In an era where scientific progress is accelerating at unprecedented rates, biopharmaceutical innovation is no longer simply a technological evolution. It constitutes a new pillar for health systems, with therapies that radically change the way rare diseases, cancer, hypercholesterolemia and an increasing range of chronic conditions are treated. Personalized medicine, gene interventions and pioneering molecules…
Einstein once said, ‘We cannot solve our problems with the same thinking we used when we created them’. This saying perhaps forms the very cornerstone- the beginning and the end- of pharmaceutical innovation: a continuous effort to seek new ways of thinking and approaching challenges, often beyond conventional limits, with the aim of providing definitive…
Pharma Innovation Forum at the Panhellenic Congress on Health Economics and Policy highlighted the critical role of data, evaluation, and European harmonization in modern pharmaceutical policy. Pharma Innovation Forum (PIF) had a strong institutional presence at the Panhellenic Congress on Health Economics and Policy, contributing substantially to the public discussion on how the country can…
Greece at a critical turning point Will Greece keep up with pharmaceutical innovation or be left behind? The event of Pharma Innovation Forum Greece (PIF), held on Wednesday, November 26, highlighted a reality that concerns us all: pharmaceutical innovation is advancing faster than ever. The question is whether Greece can -and wants to- keep up.…
The 2nd interactive workshop organized by PIF and ELLoK highlighted practical steps, institutional proposals and the importance of active citizen participation in the new era of health data. The Hellenic Cancer Federation (ELLOK), as the National Cancer Mission Hub (NCMH) of the European Mission on Cancer, in collaboration with Pharma Innovation Forum Greece (PIF) and…
At the initiative of PhARMA Innovation Forum (PIF), a broad meeting was held with the Minister of Health, Mr. Adonis Georgiadis, with the participation of SFEE and other institutional pharmaceutical bodies, in a productive and positive atmosphere, with a shared recognition of the pressure exerted by the clawback on patients and the innovation ecosystem. The…
A dialogue between PIF and ENASEL on the truth behind access to innovation. As part of the ENASEL 2025 Annual Patient Conference, the session titled “Access to Innovation Under Threat: Debunking Myths, Revealing Facts” was successfully held, co-organized by PhARMA Innovation Forum (PIF) and ENASEL. The initiative aimed to highlight, through evidence-based dialogue and data…
Imagine a patient with a rare condition in Greece who waits for years to access a new therapy. This is not an exception: reimbursement of innovative treatments in Greece is slow and only a small proportion of new therapies is available. The human cost is real. Yet biopharmaceutical science is advancing rapidly: international authorities classify…
Pharmaceutical innovation is more than a scientific or medical achievement—it is a strategic enabler for improving health outcomes, ensuring the sustainability of national healthcare systems, and driving economic growth. In Greece, this reality is becoming increasingly clear. With a population facing growing healthcare needs, limited resources, and mounting economic pressures, the integration of innovative therapies…
Biopharmaceutical research is advancing at an impressive pace, offering cutting-edge therapies that are transforming healthcare, altering the natural course of many severe diseases, and significantly improving patients’ quality of life. This progress makes pharmaceutical policy a decisive factor for the efficiency and resilience of the healthcare system, necessitating a structural revision that ensures innovation is…
